Jaeoh Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jaeoh Park has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Chan Choi
21 shared publicationsDahye Lee
21 shared publications- David Eisenbarth
Indiana University School of Medicine, Indianapolis, IN, USA
21 shared publications - Hail Kim
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
21 shared publications Dae-Sik Lim
20 shared publicationsWonyoung Choi
20 shared publications
Latest Publications
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (119) , eadz0348
Citraconate preserves T cell stemness and antitumor immunity
Metabolic perturbations in the tumor microenvironment profoundly compromise the stemlike properties and effector functions of CD8 T cells. Deciphering the metabolic circuitry that sustains T cell stemness is critical for reinvigorating tumor-infiltrating lymphocytes and augmenting immunotherapeutic efficacy. Here, we identify citraconate, an itaconate isomer, as a metabolite markedly depleted in CD8 T cells subjected to chronic antigen stimulation or hypoxic conditions. Citraconate supplementation preserves stemlike characteristics, attenuates ferroptosis, and potentiates T cell–mediated antitumor immunity. Mechanistically, citraconate maintains intracellular cyclic adenosine monophosphate (cAMP) concentrations by suppressing phosphodiesterase1A/C (PDE1A/C) expression and preserving mitochondrial integrity, thereby activating protein kinase A (PKA) signaling. This activation transcriptionally represses arachidonate-5-lipoxygenase (ALOX5), consequently reducing arachidonic acid peroxidation. Clinically, diminished ALOX5 or PDE1A expression correlates with reduced T cell exhaustion and improved responses to immune checkpoint blockade (ICB) therapy. Our findings reveal the citraconate-mediated PDE1-cAMP-ALOX5 axis as a potential therapeutic target for enhancing cancer immunotherapy.
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (119) , eadz0348
Citraconate preserves T cell stemness and antitumor immunity
Metabolic perturbations in the tumor microenvironment profoundly compromise the stemlike properties and effector functions of CD8 T cells. Deciphering the metabolic circuitry that sustains T cell stemness is critical for reinvigorating tumor-infiltrating lymphocytes and augmenting immunotherapeutic efficacy. Here, we identify citraconate, an itaconate isomer, as a metabolite markedly depleted in CD8 T cells subjected to chronic antigen stimulation or hypoxic conditions. Citraconate supplementation preserves stemlike characteristics, attenuates ferroptosis, and potentiates T cell–mediated antitumor immunity. Mechanistically, citraconate maintains intracellular cyclic adenosine monophosphate (cAMP) concentrations by suppressing phosphodiesterase1A/C (PDE1A/C) expression and preserving mitochondrial integrity, thereby activating protein kinase A (PKA) signaling. This activation transcriptionally represses arachidonate-5-lipoxygenase (ALOX5), consequently reducing arachidonic acid peroxidation. Clinically, diminished ALOX5 or PDE1A expression correlates with reduced T cell exhaustion and improved responses to immune checkpoint blockade (ICB) therapy. Our findings reveal the citraconate-mediated PDE1-cAMP-ALOX5 axis as a potential therapeutic target for enhancing cancer immunotherapy.
- 29 October 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (12) , 2185-2200
Cancer suppresses mitochondrial chaperone activity in macrophages to drive immune evasion
Contrary to tumor-infiltrating T cells with dysfunctional mitochondria, tumor-associated macrophages (TAMs) preserve their mitochondrial activity in the nutrient-limited tumor microenvironment (TME) to sustain immunosuppression. Here we identify TNF receptor-associated protein-1 (TRAP1), a mitochondrial HSP90 chaperone, as a metabolic checkpoint that restrains oxidative respiration and limits macrophage suppressive function. In the TME, TRAP1 is downregulated through TIM4–AMPK signaling, and its loss enhances immunoinhibitory activity, limits proinflammatory capacity and promotes tumor immune escape. Mechanistically, TRAP1 suppression augments electron transport chain activity and elevates the α-ketoglutarate/succinate ratio, remodeling mitochondrial homeostasis. The resulting accumulation of α-ketoglutarate further potentiates JMJD3-mediated histone demethylation, establishing transcriptional programs that reinforce an immunosuppressive state. Restoring TRAP1 by targeting TIM4 and JMJD3 reprograms TAMs, disrupts the immune-evasive TME and bolsters antitumor immunity. These findings establish TRAP1 as a critical regulator integrating metabolic and epigenetic control of suppressive TAM function and position the TRAP1 pathway as a promising target for cancer immunotherapy.
- 29 October 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (12) , 2185-2200
Cancer suppresses mitochondrial chaperone activity in macrophages to drive immune evasion
Contrary to tumor-infiltrating T cells with dysfunctional mitochondria, tumor-associated macrophages (TAMs) preserve their mitochondrial activity in the nutrient-limited tumor microenvironment (TME) to sustain immunosuppression. Here we identify TNF receptor-associated protein-1 (TRAP1), a mitochondrial HSP90 chaperone, as a metabolic checkpoint that restrains oxidative respiration and limits macrophage suppressive function. In the TME, TRAP1 is downregulated through TIM4–AMPK signaling, and its loss enhances immunoinhibitory activity, limits proinflammatory capacity and promotes tumor immune escape. Mechanistically, TRAP1 suppression augments electron transport chain activity and elevates the α-ketoglutarate/succinate ratio, remodeling mitochondrial homeostasis. The resulting accumulation of α-ketoglutarate further potentiates JMJD3-mediated histone demethylation, establishing transcriptional programs that reinforce an immunosuppressive state. Restoring TRAP1 by targeting TIM4 and JMJD3 reprograms TAMs, disrupts the immune-evasive TME and bolsters antitumor immunity. These findings establish TRAP1 as a critical regulator integrating metabolic and epigenetic control of suppressive TAM function and position the TRAP1 pathway as a promising target for cancer immunotherapy.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Table S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Table S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
The effects of PLT012 treatment were evaluated in subcutaneous tumors using syngeneic murine models.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
The effects of PLT012 treatment were evaluated in subcutaneous tumors using syngeneic murine models.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
CD8_Tex_curated_GSE_enrichment
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
CD8_Tex_curated_GSE_enrichment
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Characterization of the progression and immune profile of the MYCOE /CTNNB1N90 liver cancer mouse model in the context of lipid-rich condition.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Characterization of the progression and immune profile of the MYCOE /CTNNB1N90 liver cancer mouse model in the context of lipid-rich condition.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Gating Strategy employed to assess the immune profile in human HCC tumor tissue.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Gating Strategy employed to assess the immune profile in human HCC tumor tissue.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
An in silico analysis on POG570 to evaluate the potential of PLT012 in targeting metastatic diseases.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
An in silico analysis on POG570 to evaluate the potential of PLT012 in targeting metastatic diseases.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Table S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Table S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Characterization for TILs population and gene signatures in liver cancer mouse models following PLT012 treatment.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Characterization for TILs population and gene signatures in liver cancer mouse models following PLT012 treatment.